Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) announced that it has received agreement from the European Medicines Agency (EMA) to pursue its proposed development plan for its chikungunya virus virus-like...
Emergent BioSolutions to Participate in Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences during the first quarter of...
Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors
Emergent BioSolutions Inc. (NYSE: EBS) today announced that two members of its board of directors – Dr. Sue Bailey and Dr. Kathryn C. Zoon – have been recognized as WomenInc. magazine's 2019 Most...
Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) announced updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus...
Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day
Emergent BioSolutions Inc. (NYSE: EBS) today outlined its growth strategy over the next five years and announced its 2024 financial and operational goals during the company’s Analyst and Investor...
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the third quarter and nine months ended September 30,...
Emergent BioSolutions to Host 2019 Analyst & Investor Day
Emergent BioSolutions Inc. (NYSE: EBS) today announced that the company will host an analyst and investor day on November 21, 2019 in New York City. This event, which is designed for sellside...
Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was granted PRIority MEdicines, or PRIME,...
Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2019, recent...
Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder
Emergent BioSolutions Inc. (NYSE: EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), U.S. Department...
Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the Cantor Fitzgerald Global Healthcare Conference 2019 to be held in...
Emergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense
Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded approximately $20 million to develop and manufacture an auto-injector containing diazepam (5 mg/mL) to treat nerve...